R Bergemann

1.2k total citations
48 papers, 821 citations indexed

About

R Bergemann is a scholar working on Cardiology and Cardiovascular Medicine, Economics and Econometrics and Surgery. According to data from OpenAlex, R Bergemann has authored 48 papers receiving a total of 821 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Cardiology and Cardiovascular Medicine, 7 papers in Economics and Econometrics and 6 papers in Surgery. Recurrent topics in R Bergemann's work include Health Systems, Economic Evaluations, Quality of Life (6 papers), Venous Thromboembolism Diagnosis and Management (5 papers) and Cardiac Valve Diseases and Treatments (5 papers). R Bergemann is often cited by papers focused on Health Systems, Economic Evaluations, Quality of Life (6 papers), Venous Thromboembolism Diagnosis and Management (5 papers) and Cardiac Valve Diseases and Treatments (5 papers). R Bergemann collaborates with scholars based in Germany, United Kingdom and United States. R Bergemann's co-authors include Stefanie Maxion‐Bergemann, Florian Abel, Frank Thielecke, Beate Sander, Bernd Kirchhof, Andrew Palmer, Dieter Horstkotte, Cornelia Piper, Manfred Dahm and Detlef Hering and has published in prestigious journals such as CHEST Journal, Critical Care Medicine and Oecologia.

In The Last Decade

R Bergemann

43 papers receiving 756 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
R Bergemann Germany 15 268 220 177 154 125 48 821
John J. Fath United States 18 73 0.3× 372 1.7× 60 0.3× 202 1.3× 79 0.6× 34 1.1k
Dieter Conen Switzerland 12 204 0.8× 174 0.8× 23 0.1× 80 0.5× 113 0.9× 24 658
Ankit Sakhuja United States 17 327 1.2× 205 0.9× 25 0.1× 218 1.4× 54 0.4× 56 918
Mutsuko Moriwaki Japan 8 155 0.6× 255 1.2× 34 0.2× 170 1.1× 19 0.2× 25 750
Keiichi Sumida United States 20 147 0.5× 206 0.9× 280 1.6× 82 0.5× 8 0.1× 64 1.3k
Oluwole Adegbala United States 14 312 1.2× 158 0.7× 18 0.1× 167 1.1× 31 0.2× 67 667
Gonzalo García de Casasola Sánchez Spain 19 151 0.6× 211 1.0× 11 0.1× 101 0.7× 35 0.3× 74 946
Jeanne D. Scinto United States 14 99 0.4× 102 0.5× 16 0.1× 280 1.8× 29 0.2× 17 782
Howard Julien United States 17 343 1.3× 205 0.9× 23 0.1× 122 0.8× 10 0.1× 47 946
Lindsay Govan United Kingdom 20 104 0.4× 188 0.9× 15 0.1× 302 2.0× 26 0.2× 30 1.0k

Countries citing papers authored by R Bergemann

Since Specialization
Citations

This map shows the geographic impact of R Bergemann's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by R Bergemann with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites R Bergemann more than expected).

Fields of papers citing papers by R Bergemann

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by R Bergemann. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by R Bergemann. The network helps show where R Bergemann may publish in the future.

Co-authorship network of co-authors of R Bergemann

This figure shows the co-authorship network connecting the top 25 collaborators of R Bergemann. A scholar is included among the top collaborators of R Bergemann based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with R Bergemann. R Bergemann is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Sharma, Sheetal, et al.. (2024). OP69 Are Artificial-Intelligence-Based Literature Reviews Accepted By Health Technology Assessment Bodies?. International Journal of Technology Assessment in Health Care. 40(S1). S30–S31.
2.
3.
Maervoet, Johan, et al.. (2023). PT2 Comparing UK Value Sets and Mapping Functions for EQ-5D. Value in Health. 26(12). S503–S503. 1 indexed citations
4.
Aggarwal, Ajay, Dominic H. Moon, Sneha Kumari, Sheetal Sharma, & R Bergemann. (2020). HT3 SYSTEMATIC ASSESSMENT OF HTA DECISIONS FOR PERSONALIZED MEDICINES FOR AN ORPHAN DISEASE: ACUTE MYELOID LEUKEMIA (AML). Value in Health. 23. S6–S6. 1 indexed citations
5.
Sharma, Sheetal, et al.. (2020). PRO43 EPIDEMIOLOGY OF MYASTHENIA GRAVIS IN US, EU5 AND JAPAN: A SYSTEMATIC LITERATURE REVIEW. Value in Health. 23. S336–S336. 1 indexed citations
6.
Sharma, Neena K., et al.. (2020). PND14 QUALITY ASSESSMENT OF META-ANALYSES ON INTERVENTIONS FOR BELL'S PALSY USING AMSTAR 2. Value in Health. 23. S260–S261. 1 indexed citations
7.
Agrawal, Sachin, et al.. (2019). PCN50 INDIRECT COMPARISON OF PARP INHIBITORS IN OVARIAN CANCER: NETWORK META-ANALYSIS. Value in Health. 22. S445–S445. 1 indexed citations
8.
Kiely, David G., Orla Doyle, Harvey Jenner, et al.. (2019). Utilising artificial intelligence to determine patients at risk of a rare disease: idiopathic pulmonary arterial hypertension. Pulmonary Circulation. 9(4). 1–9. 39 indexed citations
9.
Piper, C., R Bergemann, H. D. Schulte, Reiner Körfer, & Dieter Horstkotte. (2008). Ist die Abschätzung der Progression valvulärer Aortenstenosen möglich?. DMW - Deutsche Medizinische Wochenschrift. 125(16). 484–488.
10.
Maxion‐Bergemann, Stefanie, Frank Thielecke, Florian Abel, & R Bergemann. (2006). Costs of Irritable Bowel Syndrome in the UK and US. PharmacoEconomics. 24(1). 21–37. 200 indexed citations
11.
Bergemann, R, et al.. (2006). Health-Economic Comparison of Paricalcitol, Calcitriol and Alfacalcidol for the Treatment of Secondary Hyperparathyroidism during Haemodialysis. Clinical Drug Investigation. 26(11). 629–638. 12 indexed citations
12.
Bergemann, R, et al.. (2005). International Variation in Resource Utilisation and Treatment Costs for Rheumatoid Arthritis. PharmacoEconomics. 23(3). 243–257. 32 indexed citations
13.
Hering, Detlef, Cornelia Piper, R Bergemann, et al.. (2005). Thromboembolic and Bleeding Complications Following St. Jude Medical Valve Replacement. CHEST Journal. 127(1). 53–59. 114 indexed citations
14.
Sander, Beate, et al.. (2005). Influenza treatment with neuraminidase inhibitors. The European Journal of Health Economics. 6(3). 244–252. 14 indexed citations
15.
Piper, Cornelia, R Bergemann, H. D. Schulte, Reiner Koerfer, & Dieter Horstkotte. (2003). Can progression of valvar aortic stenosis be predicted accurately?. The Annals of Thoracic Surgery. 76(3). 676–680. 15 indexed citations
16.
Bergemann, R, et al.. (1999). Economic Evaluation of the Treatment of Chronic Wounds. PharmacoEconomics. 16(4). 367–377. 16 indexed citations
17.
Kirchhof, Bernd, Andrew Palmer, Kakkar Vv, & R Bergemann. (1997). The Economic Burden of Deep Vein Thrombosis Sequelae: A Cost of Illness Analysis for Germany. Oecologia. 2(4). 40–44.
18.
Palmer, Andrew, K. Koppenhagen, Bernd Kirchhof, Ulrich Weber, & R Bergemann. (1997). Efficacy and Safety of Low Molecular Weight Heparin, Unfractionated Heparin and Warfarin for Thrombo-Embolism Prophylaxis in Orthopaedic Surgery: A Meta-Analysis of Randomised Clinical Trials. Pathophysiology of Haemostasis and Thrombosis. 27(2). 75–84. 74 indexed citations
19.
Bergemann, R, et al.. (1994). Preventive treatment of chronic bronchitis: a meta-analysis of clinical trials with a bacterial extract (OM-85 BV) and a cost-effectiveness analysis.. PubMed. 49(4). 302–7. 10 indexed citations
20.
Bergemann, R, Arno Brandt, & Walter Siegrist. (1993). Cost-Effectiveness Study of a Lipid-Lowering Therapy in Hyperlipoproteinaemia Type IIb and Type IV (Frederickson). PharmacoEconomics. 3(2). 131–139. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by John J. Fath Breakdown of academic impact, for papers by Dieter Conen Breakdown of academic impact, for papers by Ankit Sakhuja Breakdown of academic impact, for papers by Mutsuko Moriwaki Breakdown of academic impact, for papers by Keiichi Sumida Breakdown of academic impact, for papers by Oluwole Adegbala Breakdown of academic impact, for papers by Gonzalo García de Casasola Sánchez Breakdown of academic impact, for papers by Jeanne D. Scinto Breakdown of academic impact, for papers by Howard Julien Breakdown of academic impact, for papers by Lindsay Govan
Rankless by CCL
2026